Patents by Inventor Jean-Alain Fehrentz
Jean-Alain Fehrentz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8710089Abstract: The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).Type: GrantFiled: September 13, 2010Date of Patent: April 29, 2014Assignees: Zentaris GmbH, Le Centre National de la Recherche Scientifique, University of Montpellier I, University of Montpellier IIInventors: Daniel Perrissoud, Jean Martinez, Aline Moulin, Jean-Alain Fehrentz, Damien Boeglin, Luc Demange
-
Patent number: 8546435Abstract: The present invention provides novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors.Type: GrantFiled: September 16, 2011Date of Patent: October 1, 2013Assignees: AEterna Zentaris GmbH, Centre National de la Recherche Scientifique, University of Montpellier I, University of Montpellier IIInventors: Babette Aicher, Gilbert Mueller, Klaus Paulini, Lars Blumenstein, Peter Schmidt, Matthias Gerlach, Michael Teifel, Jean Martinez, Jean-Alain Fehrentz, Anne-Laure Blayo
-
Publication number: 20120083494Abstract: The present invention provides novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors.Type: ApplicationFiled: September 16, 2011Publication date: April 5, 2012Applicants: AETERNA ZENTARIS GmbH, University of Montpellier Il, University of Montpellier I, Centre National De La Recherche Scient.Inventors: Babette Aicher, Gilbert Mueller, Klaus Paulini, Lars Blumenstein, Peter Schmidt, Matthias Gerlach, Michael Teifel, Jean Martinez, Jean-Alain Fehrentz, Anne-Laure Blayo
-
Publication number: 20100331343Abstract: The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).Type: ApplicationFiled: September 13, 2010Publication date: December 30, 2010Applicants: ZENTARIS GmbH, Le Centre National De La Recherche Scientifique, University of Montpellier I, University of Montpellier IIInventors: Daniel PERRISSOUD, Jean Martinez, Aline Moulin, Jean-Alain Fehrentz, Damien Boeglin, Luc Demange
-
Patent number: 7829724Abstract: The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).Type: GrantFiled: August 11, 2006Date of Patent: November 9, 2010Assignees: Zentaris GmbH, Le Centre National de la Recherche Scientifique, University of Montpellier I, University of Montpellier IIInventors: Daniel Perrissoud, Jean Martinez, Aline Moulin, Jean-Alain Fehrentz, Damien Boeglin, Luc Demange
-
Publication number: 20090239877Abstract: The invention provides 1,2,4-triazole compounds, compositions containing those compounds, methods of treating diseases and/or disorders with those compounds and processes of manufacturing 1,2,4-triazole compounds.Type: ApplicationFiled: March 17, 2009Publication date: September 24, 2009Applicants: AETERNA ZENTARIS GmbH, CENTRE NAT DE LA RECHERCHE SCIENTIFIQUE, University of Montpellier I, University of Montpellier IIInventors: Jean-Alain Fehrentz, Mathieu Bibian, Aline Moulin, Jean Martinez
-
Patent number: 7297681Abstract: The invention relates to compounds of formula I which are useful for elevating the plasma level of growth hormone in a mammal as well as for the treatment of growth hormone secretion deficiency, growth retardation in child and metabolic disorders associated with growth hormone secretion deficiency.Type: GrantFiled: May 4, 2004Date of Patent: November 20, 2007Assignee: Æterna Zentaris GmbHInventors: Jean Martinez, Jean-Alain Fehrentz, Vincent Guerlavais
-
Publication number: 20070208061Abstract: The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).Type: ApplicationFiled: August 11, 2006Publication date: September 6, 2007Applicants: ZENTARIS GmbH, Le Centre National De La Recherche ScientifiqueInventors: Daniel PERRISSOUD, Jean MARTINEZ, Aline MOULIN, Jean-Alain FEHRENTZ, Damien BOEGLIN, Luc DEMANGE
-
Publication number: 20070037857Abstract: The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).Type: ApplicationFiled: August 11, 2006Publication date: February 15, 2007Applicants: ZENTARIS GmbH, Le Centre National De La Recherche Scientifique, University of Montpellier I, University of Montpellier IIInventors: Daniel Perrissoud, Jean Martinez, Aline Moulin, Jean-Alain Fehrentz, Damien Boeglin, Luc Demange
-
Patent number: 6861409Abstract: The invention relates to compounds of formula I which are useful for elevating the plasma level of growth hormone in a mammal as well for the treatment of growth hormone secretion deficiency, growth retardation in child and metabolic disorders associated with growth hormone secretion deficiency.Type: GrantFiled: June 13, 2001Date of Patent: March 1, 2005Assignee: Zentaris AGInventors: Jean Martinez, Jean-Alain Fehrentz, Vincent Guerlavais
-
Publication number: 20040229823Abstract: The invention relates to compounds of formula I 1Type: ApplicationFiled: May 4, 2004Publication date: November 18, 2004Applicant: Zentaris AGInventors: Jean Martinez, Jean-Alain Fehrentz, Vincent Guerlavais
-
Publication number: 20020165343Abstract: The invention relates to compounds of formula I 1Type: ApplicationFiled: June 13, 2001Publication date: November 7, 2002Inventors: Jean Martinez, Jean-Alain Fehrentz, Vincent Guerlavais
-
Patent number: 5498732Abstract: The invention relates to a process for the preparation of 5-(1-hydroxy-2-urethanethylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione derivatives, which are precursors of chiral tetramic acid derivatives.According to this process, an N-urethane-protected .alpha.-amino acid N-carboxy-anhydride is reacted with Meldrum's acid in an inert organic solvent medium in the presence of a tertiary amine.This process makes it possible to conserve the chirality of the starting material and in particular to simplify the synthesis of 4-amino-3-hydroxy acids and the derivatives thereof via the tetramic acid route.Type: GrantFiled: September 15, 1994Date of Patent: March 12, 1996Assignee: PropeptideInventors: Albert Loffet, Jean-Alain Fehrentz, Jean Martinez, Philippe-Francois Winternitz
-
Patent number: 5296354Abstract: The present invention relates to a kit for the specific assay of Angiotension II, comprising:the anti-Ang II antibody,a solution of labelled Ang II,solutions containing the Ang II standards at known and increasing concentrations,the requisite washing solution(s),a solution of anti-Ang III antibody, the said antibody exhibiting a cross-reaction with Ang II of less than 10% and preferably less than 5%,and, optionally, a solution of anti-Ang I antibody and/or a solution of anti-pentapeptide antibody and/or a solution of anti-hexapeptide antibody, the said antibodies exhibiting a cross-reaction with Ang II of less than 10% and preferably less than 5%.Type: GrantFiled: July 5, 1991Date of Patent: March 22, 1994Assignee: Elf SanofiInventors: Dominique Simon, Jean Marchand, Gabriel Badouaille, Bernard Romestand, Jean-Alain Fehrentz